Piper Jaffray Companies reiterated their overweight rating on shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) in a research note published on Tuesday morning, The Fly reports. The brokerage currently has a $17.00 price target on the biotechnology company’s stock, down from their prior price target of $35.00.
EIGR has been the topic of a number of other reports. Oppenheimer set a $34.00 price objective on shares of Eiger Biopharmaceuticals and gave the company a buy rating in a research note on Monday, October 23rd. Zacks Investment Research raised shares of Eiger Biopharmaceuticals from a hold rating to a buy rating and set a $15.00 price objective on the stock in a research note on Monday, October 16th. ValuEngine raised shares of Eiger Biopharmaceuticals from a sell rating to a hold rating in a research note on Sunday, December 31st. Roth Capital assumed coverage on shares of Eiger Biopharmaceuticals in a research note on Thursday, October 19th. They issued a buy rating and a $35.00 price objective on the stock. Finally, Ladenburg Thalmann Financial Services assumed coverage on shares of Eiger Biopharmaceuticals in a research report on Wednesday, January 3rd. They set a buy rating and a $32.00 target price on the stock. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $27.25.
Eiger Biopharmaceuticals (NASDAQ EIGR) traded down $0.05 during trading hours on Tuesday, hitting $8.85. 180,760 shares of the stock were exchanged, compared to its average volume of 422,269. The company has a debt-to-equity ratio of 1.19, a quick ratio of 5.78 and a current ratio of 5.78. Eiger Biopharmaceuticals has a 12 month low of $6.10 and a 12 month high of $16.20. The company has a market cap of $92.54, a price-to-earnings ratio of -1.67 and a beta of 2.54.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.28) by $0.18. equities analysts expect that Eiger Biopharmaceuticals will post -4.56 EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in EIGR. Bank of New York Mellon Corp lifted its position in shares of Eiger Biopharmaceuticals by 6.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 871 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of Eiger Biopharmaceuticals during the 2nd quarter valued at $272,000. Susquehanna International Group LLP acquired a new position in shares of Eiger Biopharmaceuticals during the 2nd quarter valued at $114,000. P.A.W. Capital Corp acquired a new position in shares of Eiger Biopharmaceuticals during the 3rd quarter valued at $880,000. Finally, Wedbush Securities Inc. acquired a new position in shares of Eiger Biopharmaceuticals during the 3rd quarter valued at $114,000. Institutional investors own 47.06% of the company’s stock.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.